
Search for companies, drugs, and catalysts
Search for companies, drugs, and catalysts
Phase 3
Development Phase
3
Upcoming Catalysts
0
Historical Events
2
Regulatory Approvals
FDA PDUFA Date bictegravir 75 mg/lenacapavir 50 mg (priority review)
FDA PDUFA Date bictegravir 75 mg/lenacapavir 50 mg (priority review)
1 competitor in HIV Prevention
View Full LandscapeTarget Indication
HIV Prevention
Mechanism of Action
Capsid Inhibitor
Clinical Trial
NCT04925752Last updated: 12/3/2025
Yeytuo
Yeytuo tablet is indicated in combination with safer sex practices for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection in adults and adolescents with increased HIV 1 acquisition risk, weighing at least 35 kg for: oral loading oral bridging (see sections 4.2, 4.4 and 5.1)
View on EMASunlenca
Sunlenca injection, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen (see sections 4.2 and 5.1). Sunlenca tablet, in combination with other antiretroviral(s), is indicated for the treatment of adults with multidrug resistant HIV 1 infection for whom it is otherwise not possible to construct a suppressive anti viral regimen, for oral loading prior to administration of long-acting lenacapavir injection (see sections 4.2 and 5.1).
View on EMA